BCL2 and non-small cell lung carcinoma: A large number of studies have shown that AS-IV can reduce the level of Bcl-2, promote the expression of Bax, and increase the ratio of Bax/Bcl-2, including that observed in lung cancer, non-small-cell lung cancer, and liver, colorectal, breast, and vulvar cancers.